Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations

Breadcrumb

  1. Emmes Group
  2. Taxonomy
  3. Term
  4. Other

The treatment of JRA-associated uveitis with Etanercept

Go back to Resources

The treatment of JRA-associated uveitis with Etanercept

Authors:

Location:

Go back to Resources

Umbilical cord blood transplantation in adults: results of a prospective, multi-institutional, NHLBI sponsored trial

Go back to Resources

Umbilical cord blood transplantation in adults: results of a prospective, multi-institutional, NHLBI sponsored trial

Authors:

Location:

Go back to Resources

4 Year Daclizumab Therapy for Sight Threatening Uveitis

Go back to Resources

4 Year Daclizumab Therapy for Sight Threatening Uveitis

Authors:

Location:

Go back to Resources

Ability of minority patients to find donors from an ethnically diverse cord blood bank

Go back to Resources

Ability of minority patients to find donors from an ethnically diverse cord blood bank

Authors:

Location:

Go back to Resources

Adverse clinical outcomes associated with short stature at dialysis initiation: a report of the North American Pediatric Renal Transplant Cooperative Study

Go back to Resources

Adverse clinical outcomes associated with short stature at dialysis initiation: a report of the North American Pediatric Renal Transplant Cooperative Study

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Calculated Creatinine Clearance (CCC) as the Most Promising Candidate Surrogate End Point for Clinical Trials

Go back to Resources

Calculated Creatinine Clearance (CCC) as the Most Promising Candidate Surrogate End Point for Clinical Trials

Authors:

Location:

Go back to Resources

Clinical trials referral resource. Clinical trials and NCI resources for cancer in HIV+ patients

Go back to Resources

Clinical trials referral resource. Clinical trials and NCI resources for cancer in HIV+ patients

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Comparative study of the safety, efficacy, and practice patterns of Monoclonal antibodies (MAbs) in pediatric renal transplantation (PRT)

Go back to Resources

Comparative study of the safety, efficacy, and practice patterns of Monoclonal antibodies (MAbs) in pediatric renal transplantation (PRT)

Authors:

Location:

Go back to Resources

Tacrolimus vs cyclosporine A as primary immunosuppression in pediatric renal transplantation: A NAPRTCS study

Go back to Resources

Tacrolimus vs cyclosporine A as primary immunosuppression in pediatric renal transplantation: A NAPRTCS study

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

The effect of antibody induction in simultaneous pancreas kidney (SPK) transplant patients receiving tacrolimus (TAC) and Mycophenolate Mofetil (MMF): Three-year results

Go back to Resources

The effect of antibody induction in simultaneous pancreas kidney (SPK) transplant patients receiving tacrolimus (TAC) and Mycophenolate Mofetil (MMF): Three-year results

Authors:

Location:

Go back to Resources

Pagination

  • Previous page ‹‹
  • Page 135
  • Next page ››
Subscribe to Other
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • Terms of Use
  • ISO Certification